Healthcare / Medical DevicesTaiwan
$14.35
-0.15 (-1.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-308.8M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
25.2x
↑EV/EBITDA
13.2x
↑ROE
3.3%
↑Gross Margin
27.6%
↓Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.6%
FCF CAGR
—
FCF margin
-5.3%
FCF / Net income
-0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.56B · net income $82.4M · FCF $-82.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.56B | $1.56B | $1.67B | $1.19B | $1.48B |
| Net Income | $82.4M | $82.4M | $94.0M | $2.9M | $143.5M |
| EBITDA | $208.4M | $208.4M | $205.8M | $92.6M | $254.9M |
| EPS | — | — | 0.64 | 0.02 | 1.16 |
| Gross Margin | 27.6% | 27.6% | 16.5% | 16.5% | 23.3% |
| Operating Margin | 7.7% | 7.7% | 2.4% | 0.1% | 9.4% |
| Net Margin | 5.3% | 5.3% | 5.6% | 0.2% | 9.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.31 | 0.14 | 0.42 |
| Current Ratio | 2.49 | 2.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-82.0M | $-82.0M | $-308.8M | $-434.1M | $-53.7M |
| Returns | |||||
| ROE | 3.3% | 3.3% | 3.8% | 0.1% | 7.8% |
| Valuation | |||||
| P/E | 25.18 | 25.18 | 31.09 | 1247.50 | 21.02 |
| EV/EBITDA | 13.17 | 13.17 | 16.60 | 34.72 | 13.18 |
| P/B | 0.81 | 0.81 | 1.17 | 1.34 | 1.72 |
| Growth & Yield | |||||
| Revenue Growth | -6.8% | -6.8% | 40.1% | -19.7% | — |
| EPS Growth | — | — | 3100.0% | -98.3% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.64 → n/d
Residual
-17.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.